Download PDF
Dtsch Med Wochenschr 2023; 148(23): 1498-1506
DOI: 10.1055/a-2012-0803
Dossier

Pulmonale Hypertonie im Zusammenhang mit Linksherzerkrankungen (Gruppe 2)

Pulmonary hypertension associated with left heart disease (group 2)
Max Wissmüller
,
Tobias Tichelbäcker
,
Karl Finke
,
Johannes Dohr
,
Joana Adler
,
Laurin Ochs
,
Christopher Hohmann
,
Stephan Baldus
,
Stephan Rosenkranz
› Further Information
Also available at
    Permissions and Reprints

Patienten mit Linksherzerkrankungen (LHD) weisen häufig eine pulmonale Hypertonie (PH) auf, die Einfluss auf Morbidität und Letalität hat. Dieser Beitrag bietet einen Überblick über aktuelle Entwicklungen im Kontext der PH-LHD inkl. diagnostischer Abklärung und Behandlungsstrategien. Darüber hinaus wird der aktuelle Kenntnisstand zu den pathophysiologischen Zusammenhängen bei PH-LHD, der prognostischen Relevanz hämodynamischer Parameter sowie Therapiestrategien beleuchtet. Der Artikel untermauert die Notwendigkeit für eine präzise diagnostische Abklärung und individualisierte Behandlungsstrategien bei Patienten mit PH-LHD.

Abstract

Patients with left heart disease (LHD) often display pulmonary hypertension (PH), which impacts morbidity and mortality. The pathophysiology of PH is complex and entails pulmonary congestion due to elevated left-sided filling pressures, pulmonary vasoconstriction as well as vascular remodeling. The recent ESC/ERS Guidelines on pulmonary hypertension updated the hemodynamic definitions of pulmonary hypertension in general, and the subclassification of post-capillary PH. This review summarizes recent advances in the diagnostic work-up and management strategies of PH associated with LHD. Specifically, we summarize revisited hemodynamic definitions and the characteristics of isolated post-capillary PH (IpcPH) and combined post- and pre-capillary PH (CpcPH). Furthermore, we review the current knowledge on the pathogenesis of PH-LHD, the prognostic relevance of hemodynamic parameters, and the management strategies, differentiating between treatment of the underlying left heart disease and therapies targeting the pulmonary circulation. The article emphasises the need for precise diagnostic work-up and individualized treatment strategies in patients with PH-LHD.

Kernaussagen

  • Bei Patienten mit LHD lässt sich häufig eine PH beobachten, welche erheblichen Einfluss auf Morbidität und Letalität besitzt.

  • Insbesondere Patienten mit erhöhtem PVR weisen eine schlechtere Prognose sowie eine stärkere Beeinträchtigung der Belastungstoleranz auf.

  • Dies unterstreicht die klinische Relevanz hämodynamischer Charakteristika und die Notwendigkeit einer detaillierten diagnostischen Aufarbeitung und Phänotypisierung.

  • Wichtig ist die Erkenntnis, dass bei Patienten mit LHD die primäre Ursache für eine PH in der Regel eine Erhöhung der linksseitigen Füllungsdrucke ist; dennoch können weitere Komponenten wie pulmonale Vasokonstriktion und vaskuläres Remodeling zur Erhöhung des PAP beitragen und das Ausmaß einer PH mit determinieren.

  • In Abhängigkeit des Ausmaßes dieser einzelnen Komponenten können unterschiedliche hämodynamische Phänotypen existieren.

  • Primäre Behandlungsstrategie ist eine Verminderung bzw. Normalisierung der linksseitigen Füllungsdrucke. Jedoch kann bei Patienten mit weiterhin deutlich erhöhtem PVR (d.h. > 5 WE) ein individuelles Therapiekonzept erforderlich sein.

  • Bei der Interpretation von Studienergebnissen sind die präzise Berücksichtigung der Charakteristika der eingeschlossenen Patienten (Art der LHD, Vorhandensein einer PH, Unterscheidung zwischen IpcPH und CpcPH) sowie der untersuchten Medikamentenklasse/Substanz und des beeinflussten Signalweges essenziell.

  • Weitere Studien sind notwendig, um das therapeutische Potenzial und die Sicherheit von gezielten PH-Therapien bei einzelnen Formen von Linksherzerkrankungen zu evaluieren.

Schlüsselwörter

pulmonale Hypertonie - Linksherzerkrankung - Klappenvitium - isoliert postkapilläre pulmonale Hypertonie (IpcPH) - kombiniert post- und präkapilläre pulmonale Hypertonie (CpcPH)

Keywords

pulmonary hypertension - left heart disease - valvular heart disease - isolated post-capillary PH (IpcPH) - combined post- and pre-capillary PH (CpcPH)


Publication History

Article published online:
10 November 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Humbert M, Kovacs G, Hoeper MM. et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43: 3618-3731 DOI: 10.1093/eurheartj/ehac237. (PMID: 36017548)
    CrossrefPubMedGoogle Scholar
  • 2 Rosenkranz S, Gibbs JSR, Wachter R. et al. Left ventricular heart failure and pulmonary hypertension. Eur Heart J 2016; 37: 942-954 DOI: 10.1093/eurheartj/ehv512. (PMID: 26508169)
    CrossrefPubMedGoogle Scholar
  • 3 Guazzi M, Naeije R. Pulmonary hypertension in heart failure: Pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 2017; 69: 1718-1734 DOI: 10.1016/j.jacc.2017.01.051. (PMID: 28359519)
    CrossrefPubMedGoogle Scholar
  • 4 Vachiéry JL, Tedford RJ, Rosenkranz S. et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53: 1801897 DOI: 10.1183/13993003.01897-2018. (PMID: 30545974)
    CrossrefPubMedGoogle Scholar
  • 5 Obokata M, Reddy YNV, Melenovsky V. et al. Deterioration in right ventricular structure and function over time in patients with heart failure and preserved ejection fraction. Eur Heart J 2019; 40: 689-697
    CrossrefPubMedGoogle Scholar
  • 6 Melenovsky V, Hwang SJ, Lin G. et al. Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J 2014; 35: 3452-3462
    CrossrefPubMedGoogle Scholar
  • 7 Maron BA, Hess E, Maddox TM. et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: Insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 2016; 133: 1240-1248
    CrossrefPubMedGoogle Scholar
  • 8 Douschan P, Kovacs G, Avian A. et al. Mild elevation of pulmonary arterial pressure as a predictor of mortality. Am J Respir Crit Care Med 2018; 197: 509-516 DOI: 10.1164/rccm.201706-1215OC. (PMID: 29099619)
    CrossrefPubMedGoogle Scholar
  • 9 Kolte D, Lakshmanan S, Jankowich MD. et al. Mild Pulmonary hypertension is associated with increased mortality: A systematic review and meta-Analysis. J Am Heart Assoc 2018; 7: e009729
    CrossrefPubMedGoogle Scholar
  • 10 Maron BA, Brittain EL, Hess E. et al. Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 2020; 8: 873-884
    CrossrefPubMedGoogle Scholar
  • 11 Vanderpool RR, Saul M, Nouraie M. et al. Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction. JAMA Cardiol 2018; 3: 298-306
    CrossrefPubMedGoogle Scholar
  • 12 Palazzini M, Dardi F, Manes A. et al. Pulmonary hypertension due to left heart disease: Analysis of survival according to the haemodynamic classification of the 2015 ESC/ERS guidelines and insights for future changes. Eur J Heart Fail 2018; 20: 248-255 DOI: 10.1002/ejhf.860. (PMID: 28464427)
    CrossrefPubMedGoogle Scholar
  • 13 Rosenkranz S, Howard LS, Gomberg-Maitland M. et al. Systemic consequences of pulmonary hypertension and right-sided heart failure. Circulation 2020; 141: 678-693 DOI: 10.1161/CIRCULATIONAHA.116.022362. (PMID: 32091921)
    CrossrefPubMedGoogle Scholar
  • 14 Tello K, Wan J, Dalmer A. et al. Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ Cardiovasc Imag 2019; 12: e009047 DOI: 10.1161/CIRCIMAGING.119.009047. (PMID: 31500448)
    CrossrefPubMedGoogle Scholar
  • 15 Fauvel C, Raitiere O, Boucly A. et al. Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. J Heart Lung Transplant 2022; 41: 1761-1772 DOI: 10.1016/j.healun.2022.09.005. (PMID: 36202691)
    CrossrefPubMedGoogle Scholar
  • 16 Guazzi M, Dixon D, Labate V. et al. RV Contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: Stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imag 2017; 10: 1211-1221
    CrossrefPubMedGoogle Scholar
  • 17 Huston JH, Maron BA, French J. et al. Association of mild echocardiographic pulmonary hypertension with mortality and right ventricular function. JAMA Cardiol 2019; 4: 1112-1121
    CrossrefPubMedGoogle Scholar
  • 18 McDonagh TA, Metra M, Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42: 3599-3726 DOI: 10.1093/eurheartj/ehab368. (PMID: 34447992)
    CrossrefPubMedGoogle Scholar
  • 19 Vahanian A, Beyersdorf F, Praz F. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022; 43: 561-632 DOI: 10.1093/eurheartj/ehab395. (PMID: 34453165)
    CrossrefPubMedGoogle Scholar
  • 20 Tichelbäcker T, Dumitrescu D, Gerhardt F. et al. Pulmonary hypertension and valvular heart disease. Herz 2019; 44: 491-501 DOI: 10.1007/s00059-019-4823-6. (PMID: 31312873)
    CrossrefPubMedGoogle Scholar
  • 21 Gaemperli O, Moccetti M, Surder D. et al. Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes. Heart 2012; 98: 126-132 DOI: 10.1136/heartjnl-2011-300705. (PMID: 21983251)
    CrossrefPubMedGoogle Scholar
  • 22 Tigges E, Blankenberg S, von Bardeleben RS. et al. Implication of pulmonary hypertension in patients undergoing MitraClip therapy: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2018; 20: 585-594
    CrossrefPubMedGoogle Scholar
  • 23 O’Sullivan CJ, Wenaweser P, Ceylan O. et al. Effect of pulmonary hypertension hemodynamic presentation on clinical outcomes in patients with severe symptomatic aortic valve stenosis undergoing transcatheter aortic valve implantation: insights from the new proposed pulmonary hypertension classification. Circ Cardiovasc Interv 2015; 8: e002358
    CrossrefPubMedGoogle Scholar
  • 24 Bermejo J, González-Mansilla A, Mombiela T. et al. Persistent pulmonary hypertension in corrected valvular heart disease: Hemodynamic insights and long-term survival. J Am Heart Assoc 2021; 10: e019949 DOI: 10.1161/JAHA.120.019949. (PMID: 33399006)
    CrossrefPubMedGoogle Scholar
  • 25 Bermejo J, Yotti R, García-Orta R. et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 2018; 39: 1255-1264
    CrossrefPubMedGoogle Scholar
  • 26 Abraham WT, Perl L. Implantable hemodynamic monitoring for heart failure patients. J Am Coll Cardiol 2017; 70: 389-398 DOI: 10.1016/j.jacc.2017.05.052. (PMID: 28705321)
    CrossrefPubMedGoogle Scholar
  • 27 Abraham WT, Stevenson LW, Bourge RC. et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 2016; 387: 453-461
    CrossrefPubMedGoogle Scholar
  • 28 Lindenfeld J, Zile MR, Desai AS. et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial. Lancet 2021; 398: 991-1001 DOI: 10.1016/S0140-6736(21)01754-2. (PMID: 34461042)
    CrossrefPubMedGoogle Scholar
  • 29 Shavelle DM, Desai AS, Abraham WT. et al. Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: One-year outcomes from the CardioMEMS post-approval study. Circ Heart Fail 2020; 13: e006863
    CrossrefPubMedGoogle Scholar
  • 30 Angermann C, Assmus B, Anker SD. for the MEMS-HF Investigators. et al. Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF). Eur J Heart Fail 2020; 22: 1891-1901
    CrossrefPubMedGoogle Scholar
  • 31 Aßmus B, Angermann CE, Alkhlout B. et al. Treatment response to heart failure management guided by remote pulmonary-artery-pressure-monitoring depends on presence and severity of pulmonary hypertension. Eur J Heart Fail 2022; 24: 2320-2330
    PubMedGoogle Scholar
  • 32 Tran JS, Havakuk O, McLeod JM. et al. Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction. ESC Heart Fail 2021; 8: 1706-1710
    CrossrefPubMedGoogle Scholar
  • 33 Codina P, Domingo M, Barceló E. et al. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension. ESC Heart Fail 2022; 9: 2170-2180
    CrossrefPubMedGoogle Scholar
  • 34 Mullens W, Martens P, Forouzan O. et al. Effects of dapagliflozin on congestion assessed by remote pulmonary artery pressure monitoring. ESC Heart Fail 2020; 7: 2071-2073 DOI: 10.1002/ehf2.12850. (PMID: 32588973)
    CrossrefPubMedGoogle Scholar
  • 35 Nassif ME, Qintar M, Windsor SL. et al. Empagliflozin effects on pulmonary artery pressure in patients with heart failure: Results from the EMBRACE-HF trial. Circulation 2021; 143: 1673-1686
    CrossrefPubMedGoogle Scholar
  • 36 Packer M, McMurray JJV, Krum H. et al. Long-term effect of endothelin receptor antagonism with bosentan on the morbidity and mortality of patients with severe chronic heart failure: Primary results of the ENABLE trials. JACC Heart Fail 2017; 5: 317-326
    CrossrefPubMedGoogle Scholar
  • 37 Vachiery JL, Delcroix M, Al Hiti H. et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018; 51: 1701886 DOI: 10.1183/13993003.01886-2017. (PMID: 29437943)
    CrossrefPubMedGoogle Scholar
  • 38 Shah SJ, Bonderman D, Borlaug BA. et al. A study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction and pulmonary vascular disease (SERENADE). Abstract. Presented at HFA Heart Failure; Madrid. 2022
    PubMedGoogle Scholar
  • 39 Califf RM, Adams KF, McKenna WJ. et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54 DOI: 10.1016/s0002-8703(97)70105-4. (PMID: 9266782)
    CrossrefPubMedGoogle Scholar
  • 40 Rosenkranz S, Lang IM, Blind R. et al. Pulmonary hypertension associated with left heart disease: Updated recommendations of the Cologne Consensus Conference 2018. Int J Cardiol 2018; 272S: 53-62
    CrossrefPubMedGoogle Scholar
  • 41 Cooper TJ, Cleland JGF, Guazzi M. et al. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial. Eur J Heart Fail 2022; 24: 1239-1248
    CrossrefPubMedGoogle Scholar
  • 42 Hoendermis E, Liu LCY, Hummel YM. et al. Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: A randomized controlled trial. Eur Heart J 2015; 36: 2565-2573
    CrossrefPubMedGoogle Scholar
  • 43 Guazzi M, Vicenzi M, Arena R. et al. Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124: 164-174
    CrossrefPubMedGoogle Scholar
  • 44 Opitz CF, Hoeper MM, Gibbs JSR. et al. Pre-capillary, combined, and post-capillary pulmonary hypertension: A pathophysiological continuum. J Am Coll Cardiol 2016; 68: 368-378 DOI: 10.1016/j.jacc.2016.05.047. (PMID: 27443433)
    CrossrefPubMedGoogle Scholar
  • 45 Kramer T, Dumitrescu D, Gerhardt F. et al. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. Int J Cardiol 2019; 283: 152-158
    CrossrefPubMedGoogle Scholar
  • 46 Gheorghiade M, Greene SJ, Butler J. et al. Effect of Vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED randomized trial. JAMA 2015; 314: 2251-2262
    CrossrefPubMedGoogle Scholar
  • 47 Pieske B, Maggioni AP, Lam CSP. et al. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the Soluble guanylate cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J 2017; 38: 1119-1127
    CrossrefPubMedGoogle Scholar
  • 48 Filippatos G, Maggioni AP, Lam CSP. et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail 2017; 19: 782-791
    CrossrefPubMedGoogle Scholar
  • 49 Armstrong PW, Pieske B, Anstrom KJ. et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020; 382: 1883-1893
    CrossrefPubMedGoogle Scholar
  • 50 Bonderman D, Ghio S, Felix SB. et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 2013; 128: 502-511
    CrossrefPubMedGoogle Scholar
  • 51 Dachs TM, Duca F, Rettl R. et al. Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: the haemoDYNAMIC trial. Eur Heart J 2022; 43: 3402-3413
    CrossrefPubMedGoogle Scholar
  • 52 Hoeper MM, Badesch DB, Ghofrani HA. et al. A phase 3 trial of Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 2023; 388: 1478-1490 DOI: 10.1056/NEJMoa2213558. (PMID: 36877098)
    CrossrefPubMedGoogle Scholar